Morten Hansen1, Özcan Met2, Niels Bent Larsen3, Mette Marie Rosenkilde4, Mads Hald Andersen1, Inge Marie Svane2, Gertrud Malene Hjortø5. 1. Center for Cancer Immune Therapy, Department of Haematology, Copenhagen University Hospital, Herlev, Denmark. 2. Center for Cancer Immune Therapy, Department of Haematology, Copenhagen University Hospital, Herlev, Denmark; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. 3. Department of Micro- and Nanotechnology, Technical University of Denmark, Kgs. Lyngby, Denmark. 4. Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark. 5. Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark. Electronic address: ghjortoe@sund.ku.dk.
Abstract
BACKGROUND AIMS: Maturation of dendritic cells (DCs) induces their homing from peripheral to lymphatic tissues guided by CCL21. However, in vitro matured human monocyte-derived DC cancer vaccines injected intradermally migrate poorly to lymph nodes (LNs). In vitro maturation protocols generate DCs with high (type 1 DCs) or low (prostaglandin E2 [PGE2]-DCs) autocrine CCL19 levels, which may potentially interfere with LN homing of DCs. METHODS: Employing a three-dimensional (3D) chemotaxis assay, chemokine competition/desensitization studies and short interfering RNA (siRNA) against CCL19, we analyzed the effect of autocrine CCL19 on in vitro migration of human DCs toward CCL21. RESULTS: Using human monocyte-derived DCs in a 3D chemotaxis assay, we are the first to demonstrate that CCL19 more potently induces directed migration of human DCs compared with CCL21. When comparing migration of type 1 DCs and PGE2-DCs, migration of type 1 DCs was strikingly impaired compared with PGE2-DCs, but only toward low concentrations of CCL21. When type 1 DCs were cultured overnight in fresh culture medium (reducing autocrine CCL19 levels), a rescuing effect was observed on migration toward low concentrations of CCL21 in a 3D chemotaxis assay. Finally pre-incubation with CCL19 negatively affected PGE2-DC migration, whereas silencing of CCL19 by siRNA improved type 1 DC migration. Importantly, in both cases, the effect was observed only at low concentrations of CCL21. CONCLUSIONS: Our results demonstrate that autocrine CCL19 negatively affects DC migratory potential toward CCL21, the potency difference between CCL19 and CCL21 being the underlying cause. CCL19 secretion level of in vitro matured DCs is an important indicator of DC vaccine homing potential.
BACKGROUND AIMS: Maturation of dendritic cells (DCs) induces their homing from peripheral to lymphatic tissues guided by CCL21. However, in vitro matured human monocyte-derived DC cancer vaccines injected intradermally migrate poorly to lymph nodes (LNs). In vitro maturation protocols generate DCs with high (type 1 DCs) or low (prostaglandin E2 [PGE2]-DCs) autocrine CCL19 levels, which may potentially interfere with LN homing of DCs. METHODS: Employing a three-dimensional (3D) chemotaxis assay, chemokine competition/desensitization studies and short interfering RNA (siRNA) against CCL19, we analyzed the effect of autocrine CCL19 on in vitro migration of human DCs toward CCL21. RESULTS: Using human monocyte-derived DCs in a 3D chemotaxis assay, we are the first to demonstrate that CCL19 more potently induces directed migration of human DCs compared with CCL21. When comparing migration of type 1 DCs and PGE2-DCs, migration of type 1 DCs was strikingly impaired compared with PGE2-DCs, but only toward low concentrations of CCL21. When type 1 DCs were cultured overnight in fresh culture medium (reducing autocrine CCL19 levels), a rescuing effect was observed on migration toward low concentrations of CCL21 in a 3D chemotaxis assay. Finally pre-incubation with CCL19 negatively affected PGE2-DC migration, whereas silencing of CCL19 by siRNA improved type 1 DC migration. Importantly, in both cases, the effect was observed only at low concentrations of CCL21. CONCLUSIONS: Our results demonstrate that autocrine CCL19 negatively affects DC migratory potential toward CCL21, the potency difference between CCL19 and CCL21 being the underlying cause. CCL19 secretion level of in vitro matured DCs is an important indicator of DC vaccine homing potential.
Authors: Emma Probst Brandum; Astrid Sissel Jørgensen; Marina Barrio Calvo; Katja Spiess; Francis C Peterson; Zhang Yang; Brian F Volkman; Christopher T Veldkamp; Mette Marie Rosenkilde; Christoffer Knak Goth; Gertrud Malene Hjortø Journal: Int J Mol Sci Date: 2022-01-26 Impact factor: 5.923
Authors: Astrid Sissel Jørgensen; Emma Probst Brandum; Jeppe Malthe Mikkelsen; Klaudia A Orfin; Ditte Rahbæk Boilesen; Kristoffer Lihme Egerod; Natasha A Moussouras; Frederik Vilhardt; Pawel Kalinski; Per Basse; Yen-Hsi Chen; Zhang Yang; Michael B Dwinell; Brian F Volkman; Christopher T Veldkamp; Peter Johannes Holst; Katharina Lahl; Christoffer Knak Goth; Mette Marie Rosenkilde; Gertrud Malene Hjortø Journal: Cell Mol Life Sci Date: 2021-09-29 Impact factor: 9.207
Authors: Stella J Berendam; Alexander F Koeppel; Nicole R Godfrey; Sherin J Rouhani; Amber N Woods; Anthony B Rodriguez; J David Peske; Kara L Cummings; Stephen D Turner; Victor H Engelhard Journal: Front Immunol Date: 2019-04-16 Impact factor: 7.561
Authors: Jennifer Frattolin; Daniel J Watson; Willy V Bonneuil; Matthew J Russell; Francesca Fasanella Masci; Mikaila Bandara; Bindi S Brook; Robert J B Nibbs; James E Moore Journal: Cells Date: 2021-12-07 Impact factor: 6.600